Long-term protection after primary yellow fever vaccination in elderly persons (60 years or older at the time of primary vaccination)

Long-term protection after primary yellow fever vaccination in elderly persons (60 years or older at the time of primary vaccination) - Long-term protection after yellow fever vaccination at old age (GKOUD10)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48529

Enrollment

Registered

2019-10-24

Start date

2019-11-12

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

protection after vaccination

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Participation in the clinical vaccine trial in 2008-2009 (GKOUD)

Exclusion criteria

Exclusion criteria: Receipt of an extra yellow fever vaccination after participation in the GKOUD trial

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the percentage of participants with protective YFVNA titers in the elderly group compared to the younger group, ten years after primary vaccination.	—

Secondary

Measure	Time frame
The secondary endpoint is the geometrical mean titre of yellow fever neutralizing antibodies in each study group.	—

Countries

Netherlands

Outcome results